Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

The candidate, which is still in early stages, targets the GLP-1, GIP and glucagon receptors. Novo’s blockbuster obesity and diabetes medications, Wegovy and Ozempic are GLP-1 receptor agonists, ...

Antag Therapeutics has initiated a first-in-human, double-blind Phase Ia trial of the glucose-dependent insulinotropic ...

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...

For moderate to severe hypoglycemia due to diabetes, a prescription medication containing the hormone glucagon can be delivered by injection or nasal inhalation. Hypoglycemic emergencies, in which ...

Current biomarkers of cognitive impairment in individuals with Alzheimer’s disease perform poorly. Now, a stronger predictor emerges.

Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China ...